The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most
common type being venous thromboembolism (VTE). Several risk factors for developing …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Heart failure is a common, costly, and debilitating syndrome that is associated with a highly
complex drug regimen, a large number of comorbidities, and a large and often disparate …